Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016

Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its first quarter financial results for the period ending 30 April 2016 on Thursday, 2 June 2016. 

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease DMD and the infectious disease Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics
Glyn Edwards / Richard Pye (UK office)			Tel: [phone]
Erik Ostrowski / Michelle Avery (US office)			[phone]
Cairn Financial Advisers LLP
(Nominated Adviser)
Liam Murray / Tony Rawlinson			Tel: [phone]
N+1 Singer
(Broker)
Aubrey Powell / Jen Boorer			Tel: [phone]
MacDougall Biomedical Communications
(US media contact)			Tel: [phone]
Chris Erdman / Karen Sharma			[e-mail] /
			[e-mail]
Consilium Strategic Communications
(Financial public relations, UK)			Tel: [phone]
Mary-Jane Elliott / Sue Stuart /			[e-mail]
Jessica Hodgson / Lindsey Neville